GlaxoSmithKline

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Lumen Technologies

Here we give some of our picks that we think can weather inflation effectively, without being part of the recent commodity run-up.

Stealth Buys For Inflationary Times

Innoviva

GlaxoSmithKline plc (NYSE: GSK) has agreed to sell 32 million shares in Innoviva Inc (NASDAQ: INVA) back to the royalty management company, raising $392 million, at a 3% discount or $12.25 per share. Innoviva, a royalty management company that collaborates with GSK on respiratory treatments, including Breo Ellipta, Anoro Ellipta, and Trelegy Ellipta, has counted GSK among its investors for years.

GSK Exits Respiratory Partner Innoviva In $392M Deal

Sanofi

These are two cheap stocks in an overvalued market.

Better Buy for 2021: GlaxoSmithKline or Sanofi?

Trial participants have 10 times more antibodies in their systems than patients recovering from COVID-19.

A plant-based vaccine from a GlaxoSmithKline alliance with Medicago shows strong antibody response

Glaxo (GSK) and its partner Medicago's adjuvant COVID-19 vaccine candidate induces robust neutralizing antibody and cellular immune responses in mid-stage study participants.

Glaxo/Medicago COVID-19 Vaccine Shows Strong Immune Response

WARREN, N.J., May 18, 2021 /PRNewswire/ -- GSK Consumer Healthcare (LSE/NYSE: GSK) today announced Advil, a leading over-the-counter (OTC) pain reliever worldwide, is teaming up with Emmy-nominated star and producer, Anthony Anderson, for the launch of #AfterMyShot, a new campaign that aims to help people feel prepared to manage post-COVID-19 vaccine side effects as they occur, so they can start to look forward to life after the shot.

Advil Teams Up with Actor and Comedian Anthony Anderson to Inspire People Everywhere to Reclaim Life's Possibilities After Vaccination

Gilead Sciences

Gilead and GSK have lagged many pharma peers and both still offer attractive dividends on their rather compressed prices.

Gilead Or GlaxoSmithKline? Choices In High-Yield Pharma

Interim Phase 2 trial results of GlaxoSmithKline plc (NYSE: GSK) and its collaborating partner Medicago Inc's COVID-19 vaccine candidate showed protective antibody levels ten times higher than in patients who have recovered from the disease. The vaccine generated similar immune responses in all age groups with no serious safety events in the mid-stage trial.

GlaxoSmithKline-Medicago's COVID-19 Vaccine Candidate Elicit Strong Immune Response

GlaxoSmithKline PLC (LON:GSK) and Canada's Medicago have reported positive interim Phase 2 trial data for the latter's plant-derived COVID-19 vaccine candidate. The jab has been tested in combination with GSK's pandemic adjuvant, which cuts the amount of vaccine protein required per dose, which helps speed up production.

GSK reports positive mid-trial results for second COVID-19 vaccine

GlaxoSmithKline reports positive mid-stage trial results for plant-based COVID-19 vaccine developed with Medicago

QUEBEC CITY & LONDON--(BUSINESS WIRE)--Medicago and GSK announce positive interim Phase 2 results for adjuvanted COVID-19 vaccine candidate

Medicago and GSK Announce Positive Interim Phase 2 Results for Adjuvanted COVID-19 Vaccine Candidate

Yet competition with Pfizer and Moderna could still be stiff.

Sanofi Executives Say Covid Vaccine Could Be 'Universal Booster'

GlaxoSmithKline PLC (LON:GSK) and Sanofi are planning to join the vaccine race well after their competitors as they pin their hopes on the need for boosters. The pair have received lukewarm market reaction despite posting positive mid-stage trial results for their COVID-19 vaccine.

GSK and Sanofi look to catch up in vaccine race with booster doses

GlaxoSmithKline and Sanofi plan to join vaccine race with booster doses

A Phase 3 trial to test the vaccine's efficacy is expected to start in a matter of weeks, with the vaccine showing potential to be a booster shot.

Sanofi, GSK Covid Vaccine Triggers ‘Strong Immune Response' As Firms Aim For Approval Later This Year

News will offer some some relief for GSK chief Emma Walmsley, who has been under pressure from investor

GlaxoSmithKline and Sanofi report strong results in trials of Covid vaccine

GlaxoSmithKline PLC (LON:GSK) announced that the COVID-19 vaccine developed with French giant Sanofi demonstrated strong immune responses in mid-stage trials. The jab showed 95% to 100% seroconversion following a second injection in all age groups, with acceptable tolerability and with no safety concerns.

GlaxoSmithKline, Sanofi post positive mid-stage trial results for COVID-19 vaccine

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune response s across all adult age groups in Phase 2 trial

Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial

One of the world's most closely watched coronavirus vaccine programs reported positive data on Monday from a mid-stage clinical trial, paving the way for the start of a massive human trial that could allow the shot to be authorized before the end of this year. Sanofi and GlaxoSmithKline, two of the largest vaccine-makers in the world, said in a press release that their experimental coronavirus vaccine led to strong immune responses across all ages in a study that enrolled 722 volunteers. It's a much-needed piece of positive news for the two industry leaders, which saw their vaccine effort delayed by disappointing data announced in December, and have fallen far behind rivals like Moderna, Pfizer-BioNTech, and Johnson & Johnson.

Sanofi and GlaxoSmithKline say their COVID-19 vaccine triggers a strong immune response, bolstering the late-comer program's potential as a booster shot

The two drugmakers say it might be most useful as a booster shot.

Sanofi and Glaxo Are Back With a Covid-19 Vaccine

BioNTech SE

Connect Biopharma Holdings

Fulgent Genetics

Knnate Biopharma

Karyopharm Therapeutics

Legend Biotech

aTyr Pharma

Eli Lilly

Genscript raised more than $1 billion from Hillhouse Capital in several different investments, including a $500 million commitment to Genscript's Legend Biotech CAR-T subsidiary. Shanghai Fosun Pharma formed a JV with its COVID-19 partner BioNTech to manufacture their partnered mRNA vaccine in China.

Week In Review: Genscript And Its Legend Bio Subsidiary Raise $1 Billion From Hillhouse

CureVac B.V

CureVac N.V. (NASDAQ: CVAC) and GlaxoSmithKline Plc (NYSE: GSK) have released positive early data from a preclinical study of its second-generation COVID-19 vaccine with signs that the candidate could also provide good protection against some variants of the virus.

CureVac-GSK's Second-Gen COVID-19 Vaccine Candidate Shows Encouraging Action Against Variants In Animal Study

Cardinal Health

Canadian Imperial Bank of Commerce

Cisco Systems

Chevron

Genuine Parts

Huntington Bancshares

Illinois Tool Works

Johnson & Johnson

Kinder Morgan

Leggett & Platt

Occidental Petroleum

Procter & Gamble

Philip Morris

Schlumberger

Total

ViacomCBS

Each month, we share the amount of dividend income we received and compare the results to the previous year. Until the stock market was stabilized and the first stimulus bill was passed, there were a lot of undervalued dividend stocks that we were able to add to our portfolios.

Dividend Income Summary: Bert's April 2021 Summary

Ping An Insurance Group Co of China Ltd

Choosing stocks with compelling Shiller price-earnings ratios enhances the likelihood of identifying value opportunities, in my opinion. Thus, investors may want to consider the following stocks, as their Shiller price-earnings ratios are standing below the S&P 500 Index's historical average of 16.82 as of Friday, May 7.

A Trio of Stock Picks With a Low Shiller Price-Earnings Ratio

Vir Biotechnology

– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 (sotrovimab) for the Early Treatment of COVID-19

News for GlaxoSmithKline Stock (GSK)